Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Panacea Biotec receives acceptance from CMSS for supply of bOPV
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The portfolio includes branded injectable cephalosporines for infectious diseases
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Subscribe To Our Newsletter & Stay Updated
